novo nordisk cuts prices for its glp-1 drugs. plans to slash Novo Nordisk has "no intention"

While overall persistence continues to decrease among those taking high-potency GLP-1 products after three years, persistence among those taking the drugs over a one-year period improved throughout the span of the study

FIM interventions can help overcome many common barriers to healthful eating, including cost, time, access, and knowledge

Latorraca, N

Pharmacol Res 171:105782 Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni E et al (2022) The anti-inflammatory and immunological properties of GLP-1 receptor agonists

These results, presented in 2024, provided the first solid evidence that GLP-1 drugs could meaningfully slow Alzheimers in humans

Like mazdutide, it uses a C20 fatty diacid for albumin binding and weekly pharmacokinetics, but the second receptor target is GIP rather than glucagon